Fintel reports that on October 21, 2025, Stifel reiterated coverage of DexCom (NasdaqGS:DXCM) with a Buy recommendation.

Stifel analyst Jonathan Block resumed coverage of DexCom (DXCM) with a Buy rating and $85 price target The firm’s due diligence was “upbeat” for ...

The parent of a child who wore the device to manage diabetes described failed alerts and inaccurate readings in a complaint.

San Diego-based Dexcom Inc., is the target of a class action lawsuit in U.S. district court over the company’s G7 continuous glucose monitors, an action which follows a U.S. FDA warning letter by a ...

Data generated by diabetes devices—including continuous glucose monitors, smart pens, and insulin pumps—are fundamental to ...